Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Holdings Boosted by Privium Fund Management B.V.

Privium Fund Management B.V. grew its holdings in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) by 34.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 397,650 shares of the biotechnology company’s stock after purchasing an additional 102,850 shares during the period. Rocket Pharmaceuticals makes up 1.1% of Privium Fund Management B.V.’s portfolio, making the stock its 19th biggest position. Privium Fund Management B.V. owned about 0.44% of Rocket Pharmaceuticals worth $4,998,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Signaturefd LLC raised its position in Rocket Pharmaceuticals by 319.8% during the fourth quarter. Signaturefd LLC now owns 4,916 shares of the biotechnology company’s stock valued at $62,000 after buying an additional 3,745 shares during the period. Harbour Investments Inc. lifted its position in shares of Rocket Pharmaceuticals by 51.9% in the fourth quarter. Harbour Investments Inc. now owns 5,385 shares of the biotechnology company’s stock worth $68,000 after purchasing an additional 1,840 shares in the last quarter. KBC Group NV boosted its holdings in shares of Rocket Pharmaceuticals by 159.6% during the fourth quarter. KBC Group NV now owns 5,475 shares of the biotechnology company’s stock worth $69,000 after purchasing an additional 3,366 shares during the period. E Fund Management Co. Ltd. purchased a new position in Rocket Pharmaceuticals during the fourth quarter valued at approximately $139,000. Finally, Strategic Financial Concepts LLC acquired a new position in Rocket Pharmaceuticals in the 4th quarter valued at approximately $141,000. Institutional investors and hedge funds own 98.39% of the company’s stock.

Rocket Pharmaceuticals Stock Down 5.4 %

Shares of Rocket Pharmaceuticals stock opened at $8.35 on Wednesday. Rocket Pharmaceuticals, Inc. has a 12-month low of $8.06 and a 12-month high of $28.67. The stock has a market capitalization of $890.36 million, a P/E ratio of -3.04 and a beta of 1.03. The company has a quick ratio of 6.05, a current ratio of 6.05 and a debt-to-equity ratio of 0.06. The stock has a 50 day moving average price of $10.06 and a two-hundred day moving average price of $13.79.

Rocket Pharmaceuticals (NASDAQ:RCKT) last posted its quarterly earnings data on Monday, March 3rd. The biotechnology company reported ($0.62) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.68) by $0.06. Equities analysts expect that Rocket Pharmaceuticals, Inc. will post -2.83 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on RCKT shares. Scotiabank lifted their target price on shares of Rocket Pharmaceuticals from $51.00 to $52.00 and gave the company a “sector outperform” rating in a research note on Monday, March 3rd. Leerink Partners lowered their target price on Rocket Pharmaceuticals from $46.00 to $44.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 19th. Jefferies Financial Group initiated coverage on Rocket Pharmaceuticals in a research note on Wednesday, December 18th. They set a “buy” rating and a $29.00 price target for the company. Wedbush initiated coverage on Rocket Pharmaceuticals in a research note on Monday, December 30th. They issued an “outperform” rating and a $32.00 price target for the company. Finally, BMO Capital Markets initiated coverage on shares of Rocket Pharmaceuticals in a research report on Wednesday, March 12th. They set an “outperform” rating and a $50.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $43.00.

Rocket Pharmaceuticals Company Profile

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.